SYS ONLINE
SUPPLEMENT_SCHOLAR
evidence · mechanism · dose
Experimental/Metabolic / GLP-1Research peptide

Liraglutide

aka Victoza · Saxenda

Daily GLP-1 receptor agonist with a shorter half-life than semaglutide.

Educational explainer of a research peptide. Profiles in this section deliberately omit clinical-trial citations, dosing protocols, and purchase links. Not FDA-approved as a supplement; not a recommendation to use.

Overview

Liraglutide is a once-daily GLP-1 analog with a fatty-acid chain that supports albumin binding and a roughly 13-hour half-life.

Source
  • Recombinant expression
Forms
  • Daily subcutaneous injection

Mechanism of action

Activates GLP-1 receptors for glucose-dependent insulin release, glucagon suppression, slowed gastric emptying, and central appetite reduction.

Pathways
  • · GLP-1 receptor agonism
Receptors
  • · GLP-1 receptor
Hormones
  • · Insulin
  • · Glucagon

How it acts on the body

Liraglutide was the first long-acting GLP-1 analog to see widespread clinical use. It uses the same fatty-acid albumin-binding trick as semaglutide but with a shorter chain, so dosing is daily rather than weekly.

Effects on weight loss and A1c are smaller than semaglutide or tirzepatide, but the daily dosing gives more flexibility to titrate around side effects. The mechanism, contraindications, and gastrointestinal side-effect profile are essentially identical to other GLP-1 agonists.

Hormonal & endocrine impact

How this peptide is reported to shift specific hormones and signaling molecules. Directionality reflects research literature and preclinical models, not clinical prescribing data.

Projected hormonal trajectory
Illustrative curves derived from reported direction of effect. Not measured patient data.

Curves are schematic shapes (sigmoid for increases/decreases, damped oscillation for modulation/stabilization) anchored to a 100% baseline. They communicate direction and tempo of change reported in research literature — not absolute hormone concentrations.

InsulinIncreases
Glucose-dependent secretion.
GlucagonDecreases
Postprandial suppression.
GhrelinDecreases
Indirect via delayed gastric emptying and central satiety.

Effects on the body

Decreases
Appetite
Increases
Glucose-dependent insulin secretion
Decreases
Body weight (modest)

Organ system effects

Endocrine

Glucose-dependent insulin/glucagon control.

Brain & CNS

Central satiety signaling.

Digestive / Gut

Slowed gastric emptying.

Reported effects

Drawn from preclinical research, anecdote, and small-scale clinical observation. No evidence grades are assigned — most peptides on this page lack rigorous human trials.

  • Established safety record
  • Approved for both diabetes and weight loss
  • Flexible daily dosing

Potential side effects

Common
  • · Nausea
  • · Diarrhea
  • · Constipation
Rare
  • · Gallstones
Serious
  • · Pancreatitis (rare)
  • · Thyroid C-cell tumor risk (rodent data)

Drug interactions

Sulfonylureas or insulin
Hypoglycemia risk.
moderate

Pairing context

Often combined with
  • Lifestyle program
    Improves adherence and outcome.
Avoid combining with
  • Personal or family history of MTC or MEN2
    Boxed contraindication.
Important. Research peptides described here are not FDA-approved supplements. Supplement Scholar does not endorse, recommend, or link to any source for purchase. Consult a qualified clinician before considering any peptide therapy.